‘MAKING MEDICINES MORE ACCESSIBLE’

“Novartis Singapore will hit a historical milestone in 2022 with 15 of our medicines being included in the Singapore Government Drug Subsidy List. Thus, more patients will have access to our medicine. We hope to continue this momentum throughout the year to transform the standard of care for twice as many patients, twice as fast. At Novartis, we work every day to reimagine medicine and improve and extend people’s lives. We have a clear mandate to bring our treatments to patients in a way that is as innovative as our science. We aim to bring the most value to our customers – patients, healthcare providers (HCP) and healthcare systems (HCS). By engaging in new ways of working with patients, HCPs and HCS, we can change the landscape of healthcare and be successful for decades to come. 2022 will be an exciting year for us; by putting our customers at the centre of everything we do, we will be making bold decisions on how we reimagine medicine and ultimately create value for HCS, Novartis and most importantly, patients.” - HWEE TEE POH, Managing Director, Novartis Singapore and Asian Emerging Markets